Global Inhalation CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Medical Devices & Consumables

Published: 2026-03-26

Pages: 110 Pages

Report ld: 6304232

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description

The global Inhalation CDMO market size was US$ 3472 million in 2025 and is forecast to reach a readjusted size of US$ 7226 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.

Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.

Inhalation CDMO Market Size(US$)

M= millions and B=billions

Inhalation Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that assist pharmaceutical companies in the development and production of inhalation products, such as inhalers and nebulizers. The market for inhalation CDMOs is growing steadily, driven by the increasing prevalence of respiratory diseases like asthma and COPD, and the rising demand for complex inhalation therapies. The North America and Europe are the major sales regions, although significant growth is also expected in Asia-Pacific. Market opportunities lie in the development of novel drug delivery systems, biologics, and personalized medicine, while challenges include regulatory complexities and the high cost of development. Future product trends point towards the integration of digital health technologies and sustainable packaging solutions in inhalation products.

The global Inhalation CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

Market Segmentation
By Company: 
    Lonza
    Vectura
    Iconovo
    CritiTech
    Hovione
    Recipharm
    Aptar Pharma
    Kindeva
    Sanner
    Particle Sciences
    Experic
    Enteris Biopharma
    Catalent
    HCmed
    Ritedose
    Bespak
    Proveris
    Bend Bioscience
    Renejix

Segment by Type
    Metered Dose Inhalers (MDIs)
    Dry Powder Inhalers (DPIs)
    Soft Mist Inhalers (SMIs)
    Others

Segment by Application
    Commercial
    Academic Research
    Others

By Region 
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
    North America
    Europe
    Asia-Pacific
    Latin America
    Middle East & Africa

(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Inhalation CDMO market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets 
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities 
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Inhalation CDMO value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

Table of Contents

1 Report Overview
    1.1 Study Scope
    1.2 Market by Type
        1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
        1.2.2 Metered Dose Inhalers (MDIs)
        1.2.3 Dry Powder Inhalers (DPIs)
        1.2.4 Soft Mist Inhalers (SMIs)
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
        1.3.2 Commercial
        1.3.3 Academic Research
        1.3.4 Others
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

2 Global Growth Trends
    2.1 Global Inhalation CDMO Market Perspective (2021-2032)
    2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
    2.3 Global Inhalation CDMO Market Share by Revenue, by Region (2021-2026)
    2.4 Global Inhalation CDMO Revenue Forecast by Region (2027-2032)
    2.5 Major Regions and Emerging Markets Analysis
        2.5.1 North America Inhalation CDMO Market Size and Prospective (2021-2032)
        2.5.2 Europe Inhalation CDMO Market Size and Prospective (2021-2032)
        2.5.3 Asia-Pacific Inhalation CDMO Market Size and Prospective (2021-2032)
        2.5.4 Latin America Inhalation CDMO Market Size and Prospective (2021-2032)
        2.5.5 Middle East & Africa Inhalation CDMO Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
    3.1 Global Inhalation CDMO Historical Market Size by Type (2021-2026)
    3.2 Global Inhalation CDMO Forecasted Market Size by Type (2027-2032)
    3.3 Representative Players for Different Types of Inhalation CDMO

4 Breakdown Data by Application
    4.1 Global Inhalation CDMO Historical Market Size by Application (2021-2026)
    4.2 Global Inhalation CDMO Forecasted Market Size by Application (2027-2032)
    4.3 New Sources of Growth in Inhalation CDMO Applications

5 Competitive Landscape by Players
    5.1 Global Top Players by Revenue
        5.1.1 Global Top Inhalation CDMO Players by Revenue (2021-2026)
        5.1.2 Global Inhalation CDMO Market Share by Revenue, by Players (2021-2026)
    5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    5.3 Players Covered: Ranking by Inhalation CDMO Revenue
    5.4 Global Inhalation CDMO Market Concentration Analysis
        5.4.1 Global Inhalation CDMO Market Concentration Ratio (CR5 and HHI)
        5.4.2 Global Top 10 and Top 5 Companies by Inhalation CDMO Revenue in 2025
    5.5 Global Key Players of Inhalation CDMO Head Offices and Areas Served
    5.6 Global Key Players of Inhalation CDMO, Product and Application
    5.7 Global Key Players of Inhalation CDMO, Date of Entry into This Industry
    5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
    6.1 North America Market: Players, Segments, Downstream and Major Customers
        6.1.1 North America Inhalation CDMO Revenue by Company (2021-2026)
        6.1.2 North America Market Size by Type
            6.1.2.1 North America Inhalation CDMO Market Size by Type (2021-2026)
            6.1.2.2 North America Inhalation CDMO Market Share by Type (2021-2026)
        6.1.3 North America Market Size by Application
            6.1.3.1 North America Inhalation CDMO Market Size by Application (2021-2026)
            6.1.3.2 North America Inhalation CDMO Market Share by Application (2021-2026)
        6.1.4 North America Inhalation CDMO Major Customers
        6.1.5 North America Market Trends and Opportunities
    6.2 Europe Market: Players, Segments, Downstream and Major Customers
        6.2.1 Europe Inhalation CDMO Revenue by Company (2021-2026)
        6.2.2 Europe Market Size by Type
            6.2.2.1 Europe Inhalation CDMO Market Size by Type (2021-2026)
            6.2.2.2 Europe Inhalation CDMO Market Share by Type (2021-2026)
        6.2.3 Europe Market Size by Application
            6.2.3.1 Europe Inhalation CDMO Market Size by Application (2021-2026)
            6.2.3.2 Europe Inhalation CDMO Market Share by Application (2021-2026)
        6.2.4 Europe Inhalation CDMO Major Customers
        6.2.5 Europe Market Trends and Opportunities
    6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
        6.3.1 Asia-Pacific Inhalation CDMO Revenue by Company (2021-2026)
        6.3.2 Asia-Pacific Market Size by Type
            6.3.2.1 Asia-Pacific Inhalation CDMO Market Size by Type (2021-2026)
            6.3.2.2 Asia-Pacific Inhalation CDMO Market Share by Type (2021-2026)
        6.3.3 Asia-Pacific Market Size by Application
            6.3.3.1 Asia-Pacific Inhalation CDMO Market Size by Application (2021-2026)
            6.3.3.2 Asia-Pacific Inhalation CDMO Market Share by Application (2021-2026)
        6.3.4 Asia-Pacific Inhalation CDMO Major Customers
        6.3.5 Asia-Pacific Market Trends and Opportunities
    6.4 Latin America Market: Players, Segments, Downstream and Major Customers
        6.4.1 Latin America Inhalation CDMO Revenue by Company (2021-2026)
        6.4.2 Latin America Market Size by Type
            6.4.2.1 Latin America Inhalation CDMO Market Size by Type (2021-2026)
            6.4.2.2 Latin America Inhalation CDMO Market Share by Type (2021-2026)
        6.4.3 Latin America Market Size by Application
            6.4.3.1 Latin America Inhalation CDMO Market Size by Application (2021-2026)
            6.4.3.2 Latin America Inhalation CDMO Market Share by Application (2021-2026)
        6.4.4 Latin America Inhalation CDMO Major Customers
        6.4.5 Latin America Market Trends and Opportunities
    6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
        6.5.1 Middle East & Africa Inhalation CDMO Revenue by Company (2021-2026)
        6.5.2 Middle East & Africa Market Size by Type
            6.5.2.1 Middle East & Africa Inhalation CDMO Market Size by Type (2021-2026)
            6.5.2.2 Middle East & Africa Inhalation CDMO Market Share by Type (2021-2026)
        6.5.3 Middle East & Africa Market Size by Application
            6.5.3.1 Middle East & Africa Inhalation CDMO Market Size by Application (2021-2026)
            6.5.3.2 Middle East & Africa Inhalation CDMO Market Share by Application (2021-2026)
        6.5.4 Middle East & Africa Inhalation CDMO Major Customers
        6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles
    7.1 Lonza
        7.1.1 Lonza Company Details
        7.1.2 Lonza Business Overview
        7.1.3 Lonza Inhalation CDMO Introduction
        7.1.4 Lonza Revenue in Inhalation CDMO Business (2021-2026)
        7.1.5 Lonza Recent Development
    7.2 Vectura
        7.2.1 Vectura Company Details
        7.2.2 Vectura Business Overview
        7.2.3 Vectura Inhalation CDMO Introduction
        7.2.4 Vectura Revenue in Inhalation CDMO Business (2021-2026)
        7.2.5 Vectura Recent Development
    7.3 Iconovo
        7.3.1 Iconovo Company Details
        7.3.2 Iconovo Business Overview
        7.3.3 Iconovo Inhalation CDMO Introduction
        7.3.4 Iconovo Revenue in Inhalation CDMO Business (2021-2026)
        7.3.5 Iconovo Recent Development
    7.4 CritiTech
        7.4.1 CritiTech Company Details
        7.4.2 CritiTech Business Overview
        7.4.3 CritiTech Inhalation CDMO Introduction
        7.4.4 CritiTech Revenue in Inhalation CDMO Business (2021-2026)
        7.4.5 CritiTech Recent Development
    7.5 Hovione
        7.5.1 Hovione Company Details
        7.5.2 Hovione Business Overview
        7.5.3 Hovione Inhalation CDMO Introduction
        7.5.4 Hovione Revenue in Inhalation CDMO Business (2021-2026)
        7.5.5 Hovione Recent Development
    7.6 Recipharm
        7.6.1 Recipharm Company Details
        7.6.2 Recipharm Business Overview
        7.6.3 Recipharm Inhalation CDMO Introduction
        7.6.4 Recipharm Revenue in Inhalation CDMO Business (2021-2026)
        7.6.5 Recipharm Recent Development
    7.7 Aptar Pharma
        7.7.1 Aptar Pharma Company Details
        7.7.2 Aptar Pharma Business Overview
        7.7.3 Aptar Pharma Inhalation CDMO Introduction
        7.7.4 Aptar Pharma Revenue in Inhalation CDMO Business (2021-2026)
        7.7.5 Aptar Pharma Recent Development
    7.8 Kindeva
        7.8.1 Kindeva Company Details
        7.8.2 Kindeva Business Overview
        7.8.3 Kindeva Inhalation CDMO Introduction
        7.8.4 Kindeva Revenue in Inhalation CDMO Business (2021-2026)
        7.8.5 Kindeva Recent Development
    7.9 Sanner
        7.9.1 Sanner Company Details
        7.9.2 Sanner Business Overview
        7.9.3 Sanner Inhalation CDMO Introduction
        7.9.4 Sanner Revenue in Inhalation CDMO Business (2021-2026)
        7.9.5 Sanner Recent Development
    7.10 Particle Sciences
        7.10.1 Particle Sciences Company Details
        7.10.2 Particle Sciences Business Overview
        7.10.3 Particle Sciences Inhalation CDMO Introduction
        7.10.4 Particle Sciences Revenue in Inhalation CDMO Business (2021-2026)
        7.10.5 Particle Sciences Recent Development
    7.11 Experic
        7.11.1 Experic Company Details
        7.11.2 Experic Business Overview
        7.11.3 Experic Inhalation CDMO Introduction
        7.11.4 Experic Revenue in Inhalation CDMO Business (2021-2026)
        7.11.5 Experic Recent Development
    7.12 Enteris Biopharma
        7.12.1 Enteris Biopharma Company Details
        7.12.2 Enteris Biopharma Business Overview
        7.12.3 Enteris Biopharma Inhalation CDMO Introduction
        7.12.4 Enteris Biopharma Revenue in Inhalation CDMO Business (2021-2026)
        7.12.5 Enteris Biopharma Recent Development
    7.13 Catalent
        7.13.1 Catalent Company Details
        7.13.2 Catalent Business Overview
        7.13.3 Catalent Inhalation CDMO Introduction
        7.13.4 Catalent Revenue in Inhalation CDMO Business (2021-2026)
        7.13.5 Catalent Recent Development
    7.14 HCmed
        7.14.1 HCmed Company Details
        7.14.2 HCmed Business Overview
        7.14.3 HCmed Inhalation CDMO Introduction
        7.14.4 HCmed Revenue in Inhalation CDMO Business (2021-2026)
        7.14.5 HCmed Recent Development
    7.15 Ritedose
        7.15.1 Ritedose Company Details
        7.15.2 Ritedose Business Overview
        7.15.3 Ritedose Inhalation CDMO Introduction
        7.15.4 Ritedose Revenue in Inhalation CDMO Business (2021-2026)
        7.15.5 Ritedose Recent Development
    7.16 Bespak
        7.16.1 Bespak Company Details
        7.16.2 Bespak Business Overview
        7.16.3 Bespak Inhalation CDMO Introduction
        7.16.4 Bespak Revenue in Inhalation CDMO Business (2021-2026)
        7.16.5 Bespak Recent Development
    7.17 Proveris
        7.17.1 Proveris Company Details
        7.17.2 Proveris Business Overview
        7.17.3 Proveris Inhalation CDMO Introduction
        7.17.4 Proveris Revenue in Inhalation CDMO Business (2021-2026)
        7.17.5 Proveris Recent Development
    7.18 Bend Bioscience
        7.18.1 Bend Bioscience Company Details
        7.18.2 Bend Bioscience Business Overview
        7.18.3 Bend Bioscience Inhalation CDMO Introduction
        7.18.4 Bend Bioscience Revenue in Inhalation CDMO Business (2021-2026)
        7.18.5 Bend Bioscience Recent Development
    7.19 Renejix
        7.19.1 Renejix Company Details
        7.19.2 Renejix Business Overview
        7.19.3 Renejix Inhalation CDMO Introduction
        7.19.4 Renejix Revenue in Inhalation CDMO Business (2021-2026)
        7.19.5 Renejix Recent Development

8 Inhalation CDMO Market Dynamics
    8.1 Inhalation CDMO Industry Trends
    8.2 Inhalation CDMO Market Drivers
    8.3 Inhalation CDMO Market Challenges
    8.4 Inhalation CDMO Market Restraints

9 Research Findings and Conclusion

10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Inhalation CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Global Inhalation CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 3. Global Market Inhalation CDMO Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
 Table 4. Global Inhalation CDMO Revenue (US$ Million) Market Share by Region (2021-2026)
 Table 5. Global Inhalation CDMO Revenue Share by Region (2021-2026)
 Table 6. Global Inhalation CDMO Revenue (US$ Million) Forecast by Region (2027-2032)
 Table 7. Global Inhalation CDMO Revenue Share Forecast by Region (2027-2032)
 Table 8. Global Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 9. Global Inhalation CDMO Market Share by Revenue, by Type (2021-2026)
 Table 10. Global Inhalation CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million)
 Table 11. Global Inhalation CDMO Market Share by Revenue, by Type (2027-2032)
 Table 12. Representative Players of Each Type
 Table 13. Global Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 14. Global Inhalation CDMO Market Share by Revenue, by Application (2021-2026)
 Table 15. Global Inhalation CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million)
 Table 16. Global Inhalation CDMO Market Share by Revenue, by Application (2027-2032)
 Table 17. New Sources of Growth in Inhalation CDMO Applications
 Table 18. Global Inhalation CDMO Revenue by Players (2021-2026) & (US$ Million)
 Table 19. Global Inhalation CDMO Market Share by Players (2021-2026)
 Table 20. Global Top Inhalation CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhalation CDMO as of 2025)
 Table 21. Ranking of Global Top Inhalation CDMO Companies by Revenue (US$ Million) in 2025
 Table 22. Global 5 Largest Players Market Share by Inhalation CDMO Revenue (CR5 and HHI) & (2021-2026)
 Table 23. Global Key Players of Inhalation CDMO, Headquarters and Area Served
 Table 24. Global Key Players of Inhalation CDMO, Product and Application
 Table 25. Global Key Players of Inhalation CDMO, Date of Entry into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. North America Inhalation CDMO Revenue by Company (2021-2026) & (US$ Million)
 Table 28. North America Inhalation CDMO Market Share by Revenue, by Company (2021-2026)
 Table 29. North America Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 30. North America Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 31. Europe Inhalation CDMO Revenue by Company (2021-2026) & (US$ Million)
 Table 32. Europe Inhalation CDMO Market Share by Revenue, by Company (2021-2026)
 Table 33. Europe Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 34. Europe Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 35. Asia-Pacific Inhalation CDMO Revenue by Company (2021-2026) & (US$ Million)
 Table 36. Asia-Pacific Inhalation CDMO Market Share by Revenue, by Company (2021-2026)
 Table 37. Asia-Pacific Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 38. Asia-Pacific Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 39. Latin America Inhalation CDMO Revenue by Company (2021-2026) & (US$ Million)
 Table 40. Latin America Inhalation CDMO Market Share by Revenue, by Company (2021-2026)
 Table 41. Latin America Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 42. Latin America Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 43. Middle East & Africa Inhalation CDMO Revenue by Company (2021-2026) & (US$ Million)
 Table 44. Middle East & Africa Inhalation CDMO Market Share by Revenue, by Company (2021-2026)
 Table 45. Middle East & Africa Inhalation CDMO Market Size by Type (2021-2026) & (US$ Million)
 Table 46. Middle East & Africa Inhalation CDMO Market Size by Application (2021-2026) & (US$ Million)
 Table 47. Lonza Company Details
 Table 48. Lonza Business Overview
 Table 49. Lonza Inhalation CDMO Product
 Table 50. Lonza Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 51. Lonza Recent Development
 Table 52. Vectura Company Details
 Table 53. Vectura Business Overview
 Table 54. Vectura Inhalation CDMO Product
 Table 55. Vectura Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 56. Vectura Recent Development
 Table 57. Iconovo Company Details
 Table 58. Iconovo Business Overview
 Table 59. Iconovo Inhalation CDMO Product
 Table 60. Iconovo Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 61. Iconovo Recent Development
 Table 62. CritiTech Company Details
 Table 63. CritiTech Business Overview
 Table 64. CritiTech Inhalation CDMO Product
 Table 65. CritiTech Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 66. CritiTech Recent Development
 Table 67. Hovione Company Details
 Table 68. Hovione Business Overview
 Table 69. Hovione Inhalation CDMO Product
 Table 70. Hovione Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 71. Hovione Recent Development
 Table 72. Recipharm Company Details
 Table 73. Recipharm Business Overview
 Table 74. Recipharm Inhalation CDMO Product
 Table 75. Recipharm Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 76. Recipharm Recent Development
 Table 77. Aptar Pharma Company Details
 Table 78. Aptar Pharma Business Overview
 Table 79. Aptar Pharma Inhalation CDMO Product
 Table 80. Aptar Pharma Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 81. Aptar Pharma Recent Development
 Table 82. Kindeva Company Details
 Table 83. Kindeva Business Overview
 Table 84. Kindeva Inhalation CDMO Product
 Table 85. Kindeva Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 86. Kindeva Recent Development
 Table 87. Sanner Company Details
 Table 88. Sanner Business Overview
 Table 89. Sanner Inhalation CDMO Product
 Table 90. Sanner Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 91. Sanner Recent Development
 Table 92. Particle Sciences Company Details
 Table 93. Particle Sciences Business Overview
 Table 94. Particle Sciences Inhalation CDMO Product
 Table 95. Particle Sciences Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 96. Particle Sciences Recent Development
 Table 97. Experic Company Details
 Table 98. Experic Business Overview
 Table 99. Experic Inhalation CDMO Product
 Table 100. Experic Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 101. Experic Recent Development
 Table 102. Enteris Biopharma Company Details
 Table 103. Enteris Biopharma Business Overview
 Table 104. Enteris Biopharma Inhalation CDMO Product
 Table 105. Enteris Biopharma Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 106. Enteris Biopharma Recent Development
 Table 107. Catalent Company Details
 Table 108. Catalent Business Overview
 Table 109. Catalent Inhalation CDMO Product
 Table 110. Catalent Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 111. Catalent Recent Development
 Table 112. HCmed Company Details
 Table 113. HCmed Business Overview
 Table 114. HCmed Inhalation CDMO Product
 Table 115. HCmed Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 116. HCmed Recent Development
 Table 117. Ritedose Company Details
 Table 118. Ritedose Business Overview
 Table 119. Ritedose Inhalation CDMO Product
 Table 120. Ritedose Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 121. Ritedose Recent Development
 Table 122. Bespak Company Details
 Table 123. Bespak Business Overview
 Table 124. Bespak Inhalation CDMO Product
 Table 125. Bespak Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 126. Bespak Recent Development
 Table 127. Proveris Company Details
 Table 128. Proveris Business Overview
 Table 129. Proveris Inhalation CDMO Product
 Table 130. Proveris Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 131. Proveris Recent Development
 Table 132. Bend Bioscience Company Details
 Table 133. Bend Bioscience Business Overview
 Table 134. Bend Bioscience Inhalation CDMO Product
 Table 135. Bend Bioscience Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 136. Bend Bioscience Recent Development
 Table 137. Renejix Company Details
 Table 138. Renejix Business Overview
 Table 139. Renejix Inhalation CDMO Product
 Table 140. Renejix Revenue in Inhalation CDMO Business (2021-2026) & (US$ Million)
 Table 141. Renejix Recent Development
 Table 142. Inhalation CDMO Market Trends
 Table 143. Inhalation CDMO Market Drivers
 Table 144. Inhalation CDMO Market Challenges
 Table 145. Inhalation CDMO Market Restraints
 Table 146. Research Programs/Design for This Report
 Table 147. Key Data Information from Secondary Sources
 Table 148. Key Data Information from Primary Sources


List of Figures
 Figure 1. Inhalation CDMO Product Picture
 Figure 2. Global Inhalation CDMO Market Share by Type: 2025 vs 2032
 Figure 3. Metered Dose Inhalers (MDIs) Features
 Figure 4. Dry Powder Inhalers (DPIs) Features
 Figure 5. Soft Mist Inhalers (SMIs) Features
 Figure 6. Others Features
 Figure 7. Global Inhalation CDMO Market Share by Application: 2025 vs 2032
 Figure 8. Commercial
 Figure 9. Academic Research
 Figure 10. Others
 Figure 11. Inhalation CDMO Report Years Considered
 Figure 12. Global Inhalation CDMO Market Size (US$ Million), Year-over-Year: 2021-2032
 Figure 13. Global Inhalation CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 14. Global Inhalation CDMO Market Share by Revenue, by Region: 2021 vs 2025
 Figure 15. North America Inhalation CDMO Revenue (US$ Million) Growth Rate (2021-2032)
 Figure 16. Europe Inhalation CDMO Revenue (US$ Million) Growth Rate (2021-2032)
 Figure 17. Asia-Pacific Inhalation CDMO Revenue (US$ Million) Growth Rate (2021-2032)
 Figure 18. Latin America Inhalation CDMO Revenue (US$ Million) Growth Rate (2021-2032)
 Figure 19. Middle East & Africa Inhalation CDMO Revenue (US$ Million) Growth Rate (2021-2032)
 Figure 20. Global Inhalation CDMO Market Share by Players in 2025
 Figure 21. Global Top Inhalation CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhalation CDMO as of 2025)
 Figure 22. The Top 10 and 5 Players Market Share by Inhalation CDMO Revenue in 2025
 Figure 23. North America Inhalation CDMO Market Share by Type (2021-2026)
 Figure 24. North America Inhalation CDMO Market Share by Application (2021-2026)
 Figure 25. Europe Inhalation CDMO Market Share by Type (2021-2026)
 Figure 26. Europe Inhalation CDMO Market Share by Application (2021-2026)
 Figure 27. Asia-Pacific Inhalation CDMO Market Share by Type (2021-2026)
 Figure 28. Asia-Pacific Inhalation CDMO Market Share by Application (2021-2026)
 Figure 29. Latin America Inhalation CDMO Market Share by Type (2021-2026)
 Figure 30. Latin America Inhalation CDMO Market Share by Application (2021-2026)
 Figure 31. Middle East & Africa Inhalation CDMO Market Share by Type (2021-2026)
 Figure 32. Middle East & Africa Inhalation CDMO Market Share by Application (2021-2026)
 Figure 33. Lonza Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 34. Vectura Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 35. Iconovo Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 36. CritiTech Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 37. Hovione Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 38. Recipharm Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 39. Aptar Pharma Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 40. Kindeva Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 41. Sanner Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 42. Particle Sciences Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 43. Experic Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 44. Enteris Biopharma Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 45. Catalent Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 46. HCmed Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 47. Ritedose Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 48. Bespak Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 49. Proveris Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 50. Bend Bioscience Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 51. Renejix Revenue Growth Rate in Inhalation CDMO Business (2021-2026)
 Figure 52. Bottom-up and Top-down Approaches for This Report
 Figure 53. Data Triangulation
 Figure 54. Key Executives Interviewed

Description

The global Inhalation CDMO market size was US$ 3472 million in 2025 and is forecast to reach a readjusted size of US$ 7226 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.

Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.

Inhalation Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that assist pharmaceutical companies in the development and production of inhalation products, such as inhalers and nebulizers. The market for inhalation CDMOs is growing steadily, driven by the increasing prevalence of respiratory diseases like asthma and COPD, and the rising demand for complex inhalation therapies. The North America and Europe are the major sales regions, although significant growth is also expected in Asia-Pacific. Market opportunities lie in the development of novel drug delivery systems, biologics, and personalized medicine, while challenges include regulatory complexities and the high cost of development. Future product trends point towards the integration of digital health technologies and sustainable packaging solutions in inhalation products.

The global Inhalation CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.

Market Segmentation
By Company: 
    Lonza
    Vectura
    Iconovo
    CritiTech
    Hovione
    Recipharm
    Aptar Pharma
    Kindeva
    Sanner
    Particle Sciences
    Experic
    Enteris Biopharma
    Catalent
    HCmed
    Ritedose
    Bespak
    Proveris
    Bend Bioscience
    Renejix

Segment by Type
    Metered Dose Inhalers (MDIs)
    Dry Powder Inhalers (DPIs)
    Soft Mist Inhalers (SMIs)
    Others

Segment by Application
    Commercial
    Academic Research
    Others

By Region 
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
    North America
    Europe
    Asia-Pacific
    Latin America
    Middle East & Africa

(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Inhalation CDMO market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets 
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities 
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Inhalation CDMO value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

undefined

Related Reports

Global Inhalation CDMO Market Insights, Forecast to 2030
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 148
USD 4900.00
(Single User License)
Global and United States Inhalation CDMO Market Report & Forecast 2024-2030
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 135
USD 4350.00
(Single User License)
Global Inhalation CDMO Market Research Report 2024
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 94
USD 2900.00
(Single User License)
Global Inhalation CDMO Market Research Report 2025
The global market for Inhalation CDMO was valued at US$ 3154 million in the year 2024 and is projected to reach a revised size of US$ 6564 million by 2031, growing at a CAGR of 11.2% during the forecast period.
Published: 2025-11-03
Pages: 93
USD 2900.00
(Single User License)
Inhalation CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Inhalation CDMO was estimated to be worth US$ 3154 million in 2024 and is forecast to a readjusted size of US$ 6564 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Published: 2025-11-03
Pages: 126
USD 3950.00
(Single User License)
Global Inhalation CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Inhalation CDMO market size was US$ 3154 million in 2024 and is forecast to a readjusted size of US$ 6564 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Published: 2025-11-03
Pages: 102
USD 4250.00
(Single User License)
Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Inhalation CDMO market is projected to grow from US$ 3154 million in 2024 to US$ 6564 million by 2031, at a CAGR of 11.2% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-03
Pages: 149
USD 4900.00
(Single User License)
Global Inhalation CDMO Market Research Report 2026
The global Inhalation CDMO market was valued at US$ 3472 million in 2025 and is anticipated to reach US$ 7226 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 138
USD 2900.00
(Single User License)
Inhalation CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Inhalation CDMO was estimated to be worth US$ 3472 million in 2025 and is projected to reach US$ 7226 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 134
USD 3950.00
(Single User License)
Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Inhalation CDMO market is projected to grow from US$ 3472 million in 2025 to US$ 7226 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 157
USD 4900.00
(Single User License)

Global Inhalation CDMO Market Insights, Forecast to 2030
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 148
USD 4900.00 (Single User License)
Global and United States Inhalation CDMO Market Report & Forecast 2024-2030
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 135
USD 4350.00 (Single User License)
Global Inhalation CDMO Market Research Report 2024
Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.
Published: 2024-09-05
Pages: 94
USD 2900.00 (Single User License)
Global Inhalation CDMO Market Research Report 2025
The global market for Inhalation CDMO was valued at US$ 3154 million in the year 2024 and is projected to reach a revised size of US$ 6564 million by 2031, growing at a CAGR of 11.2% during the forecast period.
Published: 2025-11-03
Pages: 93
USD 2900.00 (Single User License)
Inhalation CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Inhalation CDMO was estimated to be worth US$ 3154 million in 2024 and is forecast to a readjusted size of US$ 6564 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Published: 2025-11-03
Pages: 126
USD 3950.00 (Single User License)
Global Inhalation CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Inhalation CDMO market size was US$ 3154 million in 2024 and is forecast to a readjusted size of US$ 6564 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Published: 2025-11-03
Pages: 102
USD 4250.00 (Single User License)
Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Inhalation CDMO market is projected to grow from US$ 3154 million in 2024 to US$ 6564 million by 2031, at a CAGR of 11.2% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-11-03
Pages: 149
USD 4900.00 (Single User License)
Global Inhalation CDMO Market Research Report 2026
The global Inhalation CDMO market was valued at US$ 3472 million in 2025 and is anticipated to reach US$ 7226 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 138
USD 2900.00 (Single User License)
Inhalation CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Inhalation CDMO was estimated to be worth US$ 3472 million in 2025 and is projected to reach US$ 7226 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 134
USD 3950.00 (Single User License)
Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Inhalation CDMO market is projected to grow from US$ 3472 million in 2025 to US$ 7226 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 157
USD 4900.00 (Single User License)